mage-a3 and ny-eso-1
Biologicalexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00090493)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cancer/testis antigen 1Immunity, active
Cancer/testis antigen 1 immunity, active
- Melanoma-associated antigen 3Immunity, active
MAGEA3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mage-a3 and ny-eso-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00090493 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2004 | Hoosier Cancer Research Network, Myeloma Institute for Research & Therapy |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Myeloma Institute for Research & Therapy | Academic/Hospital | 1 | 0 | 1 | 2004 |
2 organizations
Page 1 / 1